• Odyssey filed for US and global patent protection on its novel breath-propelled, intranasal brain-drug delivery device that effectively deposits concentrated drug deep into the nasal cavity for the treatment of CNS injury disease or disorder
• The application follows the successful completion of the second Cohort of Odyssey’s Phase I MAD clinical trial, which saw the effective use of the device and a proven safety profile for the company’s concussion pharmaceutical treatment
• Michael Redmond, the company’s CEO, has expressed the company’s pleasure in the functionality of the device, citing how it provides a significant opportunity and advantage for the treatment of neurological conditions
• The patent application bolsters Odyssey’s growing list of medical devices, which currently comprise a CardioMap, a heart monitoring and screening device, as well as Save-A-Life, a handheld choking rescue device

Odyssey Health (OTC: ODYY), a medical enterprise focused on unique, life-saving medical products that offer clinical advantages to unmet clinical needs, just announced filing for the United States and global patent protection on its novel breath-propelled, intranasal brain-drug delivery device. This comes on the heels of the successful completion of the second Cohort of its Phase I Multi-Day Ascending Dosing (“MAD”) clinical trial, which saw the successful use of the device, and a proven safety profile of the company’s concussion pharmaceutical treatment. “Following the completion of this Phase I trial, I am very pleased with the safety profile of our concussion pharmaceutical treatment,” noted Michael Redmond, Odyssey’s CEO. “I’m equally pleased that the intranasal drug/device combination has functioned nicely and has been easy to operate in the clinical setting,” he added (https://ibn.fm/0Gf75). The Nasal Device was designed to create an adequate airflow for depositing concentrated drug deep into the nasal cavity and onto the olfactory region for quick and direct diffusion into the brain to treat central nervous system (“CNS”) injury, disease, or disorder. The concussion drug candidate is designed to be administered within a few minutes of a concussive episode, thereby inducing intracellular steroid receptors in brain cells and activating multiple gene response elements that reduce swelling, oxidative stress, and inflammation in the brain. This, in turn, restores proper blood flow to the brain while also avoiding drug-induced fatigue or cognitive decline associated with the prolonged use of drugs associated with concussion treatment (https://ibn.fm/mHCkO). The patent application bolsters Odyssey’s growing list of medical devices that currently comprise a CardioMap – a heart monitoring and screening device for early detection of coronary artery disease, as well as Save-A-Life- a handheld choking rescue device. Mr. Redmond has expressed the company’s pleasure in the functionality and performance of the Nasal Device, citing how it provides a significant opportunity and advantage for treating neurological conditions. “We were very pleased with the functionality and performance of the Nasal Device during the Phase I study and its administration of Odyssey’s concussion drug. The ability to get drugs for neurological conditions delivered directly into the brain rapidly at effective levels while simultaneously having less concern for side effects is a huge advantage in the development of safe and efficacious treatments,” he noted. “Odyssey’s novel Nasal Device provides that opportunity and advantage,” he added (https://ibn.fm/RBlhR). Odyssey is still identifying Phase II trial sites and structuring the study design with the site’s medical leadership and the Odyssey Medical Advisors. The company looks to make further use of the Nasal Device in this phase of the study, while also building on the success of the previous research as it works towards approval by the U.S. Food and Drug Administration (“FDA”). For more information, visit the company’s website at www.OdysseyHealthInc.com. NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY

• In June 2020, CNS’ lead drug candidate, Berubicin, received Orphan Drug designation from the FDA. In June 2021, it received Fast Track designation following positive results from an extensive clinical study that saw 44% of the patients post a clinical response, with one Durable Complete Response
• With GBM having a survival rate of only 6.8% and an average length of survival of only eight months, Berubicin is showing tremendous potential, and CNS is leading the charge to find a potential treatment option for the disease
• CNS’ management is optimistic about its lead drug candidate and continues to explore the potential treatment of other conditions such as lymphomas, lung and breast cancers

CNS Pharmaceuticals (NASDAQ: CNSP), a clinical stage biotechnology company, recognizes the growing problem of metastatic cancers of the brain and central nervous system. More importantly, it recognizes how few and largely ineffective current solutions are available, ultimately contributing to higher mortality rates and a poor quality of life for victims with such conditions. This understanding led to the introduction of Berubicin, the company’s lead drug candidate aimed at treating Glioblastoma Multiforme (“GBM”), with the potential to also deal with other central nervous system malignancies. In June 2020, Berubicin received Orphan Drug designation from the United States Food and Drug Administration (“FDA”) and Fast Track designation in June 2021. These designations came in the wake of positive results following an extensive clinical study in which 44% of patients showed a clinical response of stable disease or better, with one Durable Complete Response. This was a huge milestone for the industry, particularly since over 10,000 individuals with GBM succumb to the disease annually, given its five-year survival rate of only 6.8%. In addition, the condition has an average length of survival for patients of only eight months (https://ibn.fm/mzJy3). “Against the backdrop of statistics that show the aggressiveness of GBM, CNS is leading the charge to find a potential treatment option for the disease,” notes a recent article (https://ibn.fm/8z75X). CNS’ Berubicin, an anthracycline chemotherapy agent, has appeared to demonstrate, based on limited clinical data, the ability to cross the blood-brain barrier to target tumors directly. This has set it apart from other more mainstream anthracyclines, allowing it to achieve more significant outcomes and a potential solution for patients with GBM and other brain tumors. According to the American Cancer Society, about 25,050 malignant tumors of the brain and spinal code will be diagnosed in the United States in 2022 alone. In addition, the society projects that about 18,280 people will die from brain and spinal cord tumors this year (https://ibn.fm/ldQYJ). Cancer.net further projects that about 4,170 children under the age of 15 will also be diagnosed with a brain or CNS tumor this year in the United States (https://ibn.fm/GYQ57). With such numbers, one would understand why CNS received its Fast Track designation from the FDA. Its research so far is the most promising in treating such conditions. Berubicin could potentially help save thousands of people every year and reduce such conditions as GBM to treatable and manageable ailments. CNS’ management is optimistic about prospects for its lead drug candidate. It continues to explore the potential treatment of other conditions such as lymphomas, lung and breast cancers. The company is also expanding its global presence, having already received clinical approvals in Switzerland, France, and Spain. It expects to utilize the Fast Track designation to build on the studies conducted so far to achieve its organizational goals and offer a viable treatment for patients with GBM. “Our focus and priorities remain on advancing our clinical development program for Berubicin to ultimately bring meaningful treatment to GBM patients, families and clinicians, who currently have extremely limited and often ineffective treatment options,” notes John Climaco, CNS’ Chief Executive officer (“CEO”) (https://ibn.fm/IdOem). For more information, visit the company’s website at www.CNSPharma.com. NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• Eloro Resources Ltd. Owns a 98% interest in Minera Tupiza with an option to acquire 99% interest in a neighboring highly sought after, royalty-free property in southern Bolivia
• Eloro has an option to acquire a 99% interest in the 9 square km, highly prospective Iska Iska Property, which hosts a major silver-tin polymetallic porphyry-epithermal complex located 4,000m above sea level

Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF) (FSE: P2QM), a publicly traded exploration and mine development company, established in 1985 with a portfolio of gold and base-metal properties in Bolivia, Peru and Quebec.

Polymetallic Project in Bolivia

Bolivia’s modern mining laws and supportive political environment have made mining the largest contributor, at 30%, to the Bolivian economy. The country has a simple tax structure, no capital controls, 0% VAT on mining/industrial equipment, and uncomplicated mining laws.

Currently, Eloro owns a 98% interest in Minera Tupiza. with an option to acquire a 99% interest in the neighboring Iska Iska, a 9 square km silver-tin polymetallic property. Iska Iska is a highly sought after road-accessible, royalty-free property located near Minera Tupiza in the Potosi Department of southern Bolivia with easy access to seaports.

The exploration program is conducting 81,936 meters of diamond drilling and has four drill rigs on site. They have uncovered high metal values within an immense system. Mineralization has been encountered in every one of the 120 drill holes to date.

Eloro is committed to the well being of this historical mining region. The company has sponsored the local school and sports, is conducting environmental study and community discussions, and has hired a 100% Bolivian on-site team.

For more information, visit the company’s website at www.EloroResources.com.

NOTE TO INVESTORS: The latest news and updates relating to ELRRF are available in the company’s newsroom at https://ibn.fm/ELRRF

• Freight Technologies recently announced receipt of a two-year commitment from Kimberly Clark De Mexico, SAB de CV (“KCM”), that will significantly expand its Fr8PrivateFleet product
• Fr8Tech introduced Fr8PrivateFleet at the end of 2021 through its wholly owned subsidiary Freight App, Inc.capacity
• The product solves shippers’ need to secure freight over time rather than on a trip-by-trip basis and provides carriers, who can deliver the shipper’s loads based on this criterion, with a steady stream of employment opportunities and revenue
• The two-year commitment is set to more than triple Fr8Tech’s capacity in the Fr8PrivateFleet product over three months

Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”), a company specializing in creating and providing supply chain optimization and automation solutions, and Freight App, Inc. (“Fr8App”), its wholly owned subsidiary, have always sought to create offerings that contribute to their clients’ success by improving efficiency and profitability. This operational principle is exemplified by, among others, the company’s technology solution for committed planning, Fr8PrivateFleet, which was launched late last year (https://ibn.fm/IuryE). Designed to help solve shippers’ needs to secure freight capacity over time rather than on a trip-by-trip basis and guarantee carriers a steady stream of revenue, Fr8PrivateFleet matches carriers who have the capacity to carry a predetermined amount of load over a stated period, with shippers. To take advantage of the convenience offered, shippers pay for the capacity they require, while the carriers commit to using Fr8Tech’s B2B marketplace, known as Fr8App, to operate all of their loads and track the progress of their loads.  Active tracking of the loads and their progress helps improve security for all parties. The advantages of Fr8PrivateFleet persuaded new and existing Fr8App customers to integrate it into their operations, among them the product’s first client, Kimberly Clark de Mexico, SAB de C.V. (“KCM”), and one of Mexico’s largest food producers (https://ibn.fm/hUYKs). Over the months since Fr8Tech announced KCM as Fr8PrivateFleet’s first client in February this year, the relationship has expanded significantly. For instance, in September, Fr8Tech announced it would support other logistics services for KCM in addition to offering the committed capacity planning product. These include dedicated truck service on the Fr8App platform, traditional spot services within domestic Mexico, and cross-border logistics for shipments from Mexico to the United States and Canada (https://ibn.fm/qarKR). In a development that further expands this relationship, Fr8Tech recently announced it had secured a two-year commitment from KCM to expand its fleet product. The commitment, once fulfilled, is estimated to triple Fr8Tech’s capacity in its Fr8PrivateFleet solution over the next three months, according to an October 27 news release (https://ibn.fm/6F1Yd). “It is very rewarding to receive this commitment, which we will begin to fulfill as soon as we secure the capacity required to do so,” commented Luisa Lopez, COO of Fr8App. “An attractive feature of a longer-term contract is that it secures a stream of steady business on our Fr8App platform over the term of the contract. As a company, we have invested a significant amount of time and resources in developing the Fr8PrivateFleet product, and it is very encouraging to receive a commitment of this size from such an important company in this segment.” Having dedicated time and money over the past year to expand its domestic freight and traffic offerings in both Mexico and the United States, Fr8Tech CEO Javier Selgas notes, the company “trusts that this is the first in a number of new agreements that we will secure over the coming months in relation to our Mexico domestic market offerings. We are only beginning to see a return on this important investment by our company and its investors.” For more information, visit the company’s website at www.Fr8Technologies.com. NOTE TO INVESTORS: The latest news and updates relating to FRGT are available in the company’s newsroom at https://ibn.fm/FRGT Corporate Communications IBN (InvestorBrandNetwork) Los Angeles, California www.InvestorBrandNetwork.com 310.299.1717 Office Editor@InvestorBrandNetwork.com

• Solar is blooming; from 2020 to 2021, residential solar power grew by 34%
• In 2022, Americans are increasingly going solar for environmental, health and financial reasons: 8% of US surveyed homeowners have installed solar panels – up from 6% in 2019 and 4% in 2016
• GeoSolar is poised to capitalize on this growth potential with its SmartGreen(TM) Home system that helps American homeowners tackle both environmental and financial issues at once

In a world unsettled by rising fuel costs and heightened energy uncertainty, solar emerges as part of a potential solution. Consequently, the sector is booming, transforming from a niche investment driven by ecological rather than monetary factors into a new mainstream investment opportunity that seeks to achieve both environmental and economic goals. As a company offering technology designed to harness energy from the earth and sun to power homes without the use of fossil fuels, GeoSolar Technologies (“GST”) appears well-positioned at the front of what may look like an eco-friendly revolution spurring more and more Americans to go solar. Although residential solar power currently accounts for only a fraction of the total US electricity, the sector has continued to snowball over recent years. This includes a period of considerable disruption due to obstacles such as COVID-19-related supply chain challenges and import restrictions. From 2020 to 2021 only, residential solar power grew from 2.9 gigawatts to 3.9-gigawatt installations, which makes a 34% growth rate (https://ibn.fm/Tusig). With new legislation that enables larger investments in renewable energy and measures to address climate change, including a 30% solar tax credit, the industry is expected to accelerate its growth. A Pew Research Center survey conducted in January, before the announcement of federal tax incentives, reports that 8% of surveyed homeowners have already installed solar panels – a significant growth from 6% in a 2019 and 4% in 2016. In addition, 39% have given serious consideration to this possibility over the past year. Most homeowners said helping the environment and improving health were their motivations for installing solar panels or considering doing so, while financial incentives also played a part. But there is a long road ahead of solar, particularly for the residential segment of the sector. According to the U.S. Energy Information Administration (“EIA”), around 3.7% of U.S. single-family homes generated electricity from small-scale solar arrays in 2020 (https://ibn.fm/NfLiU). Compared to large utility-scale solar, which includes facilities such as solar panel farms, residential solar still generates less electricity-and all solar power together generates only a small fraction of the electricity consumed in the US. For example, last year, solar generated just 3% of all utility-scale electricity, dwarfed by natural gas (38%) or coal (22%) (https://ibn.fm/6dvof). Notwithstanding its small size, solar adoption in all sectors, from residential to the utility-scale, is expected to explode over the next decade. By 2024 only, the capacity added is expected to rise to a level five times bigger than what was observed in 2020. Due to its rapid growth, the sector attracts increasing attention from investors. It is estimated that investment in solar could reach $321 billion in 2030, which is almost double the figure of $177 billion expected under current policy, leading to nearly $3.5 trillion in cumulative capital investment in new American energy supply over the next ten years. As a readily available and renewable energy source, solar could become one of the lowest-cost energy options in the years to come. Confident that the world is in the early stages of what might be one of the most consequential transitions in human history — the shift from a fossil fuel-driven present to a clean all-electric future — GeoSolar seeks to lead Americans toward a greener future. Its SmartGreen(TM) Home system, designed for newly built and existing residences, offers homeowners zero or no utility bills and a healthier carbon-free living environment. With inflation soaring to the highest levels in decades and the threat of climate crisis becoming increasingly palpable, GeoSolar seeks to offer American homeowners solutions that help them save money and help the planet all at once. For more information, visit the company’s website at www.GeoSolarPlus.com. NOTE TO INVESTORS: The latest news and updates relating to GeoSolar Technologies are available in the company’s newsroom at https://ibn.fm/GST

• Lexaria’s HYPER-H21-4 human clinical study was a success, producing favorable results in treating hypertension when comparing the company’s patented DehydraTECH(TM) CBD with a placebo
• According to a Zacks SCR report, the findings support their $15 share valuation of the company
• Zacks expects Lexaria to penetrate global markets for hypertension, nicotine delivery and antiviral products
• The hypertension drug market is expected to grow to over $34 billion through 2030, with North America anticipated to hold 35% of the market share

According to the World Health Organization (“WHO”), approximately 1.13 billion people worldwide suffer from hypertension (high blood pressure), with only one in five being treated or under control. The hypertension drug market size in 2021 was valued at $25,394 million and is expected to grow at a CAGR of 3.4% through 2030, resulting in an estimated value of $34,072 million. The North American market is expected to lead with more than 35% of the world market share (https://ibn.fm/QQ33h). Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently released impressive results from its fourth and most comprehensive hypertension study, HYPER-H21-4. The study, structured as a randomized, double-blind, placebo-controlled cross-over study, dosed 66 male and female volunteers between the ages of 40-70 with stage 1 or 2 hypertension, comparing the company’s patented DehydraTECH(TM) cannabidiol (“CBD”) against a placebo. The study showed patients receiving placebo doses trended toward increases in blood pressure (“BP”) during the period of the study compared to baseline, while the average BP measured by each of mean arterial BP, systolic BP and diastolic BP significantly decreased from baseline when dosed with DehydraTECH-CBD; and those decreases were maintained during the full 5 weeks of dosing  – with no serious adverse events or hepatic changes occurring (https://ibn.fm/38KF3). Lexaria’s DehydraTECH technology is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients, increasing effectiveness and improving the way that active pharmaceutical ingredients (“APIs”) enter the bloodstream. In 2021, animal studies demonstrated that DehydraTECH elevated drug quantities across the blood-brain barrier by as much as 1,700%, which initiated further investigations  and opened the possibilities for improved drug delivery. The benefits of using Lexaria’s patented technology include the following:

• Improves the speed of onset, with effects felt in minutes
• Increases bioavailability by more effectively delivering the drug into the bloodstream
• Increases brain absorption, with testing suggesting up to 10x improvement
• Reduces drug administration costs with a higher ratio of drug delivery

Lexaria announced the enrollment for HYPER-H21-4 in an April 19 press release, and dosing began ahead of schedule, with completion on July 27, with no serious adverse events reported as a result of the dosing. The maximum dose levels in the study were roughly 5 mg/kg/day, which is significantly lower than maximum dose levels practiced for other regulator-approved pharmaceutical CBD applications., The company will use data from the study to support its Investigational New Drug (“IND”) application with the FDA. According to a Zacks Small-Cap Research (“Zacks SCR”) report, the company’s next steps for the hypertension program will be to submit and receive clearance for an IND application, and the application and IND clearance will support the start of the Phase Ib study slated for 2023 (https://ibn.fm/L7LRB). Longer term goals for the program are to find a partner who will advance the work to a registrational study and send it to the FDA for approval. While this is several years away, the data that has been released so far is supportive of further development. Zacks SCR forecasts penetration by Lexaria into global markets for hypertension, nicotine delivery, and antiviral product categories. The Zacks SCR valuation of $15 per share assumes a 2024 regulatory approval and commercialization of DehydraTECH CBD in the United States and developed markets – a valuation maintained throughout the report. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• While economies worldwide are struggling to control spiking inflation rates, REZYFi, a mortgage lender servicing non-traditional as well as other loans, sees unique financial opportunities
• Through the use of proprietary automated machine learning and associated technologies, together with preparations to launch a high-margin cannabis division later this year to serve an industry in need of loan origination options, REZYFi is working to grow its operation
• RZFI is licensed in more than 30 U.S. states and expects to expand its loan origination services to all remaining states in coming months

Economic challenges resulting from governmental efforts to tame inflation could in turn create new opportunities for hard-to-finance sector lenders, especially as mortgage rates eventually fall as recently suggested by CNN Business (https://ibn.fm/EBSYB). The fight against inflation has delivered successes in the United States — what investment bank Goldman Sachs refers to as “remarkable” progress in slowing the US economy and easing the concerning imbalance between supply and demand in the jobs market, though Goldman also warns against going too far in the inflation battle. “Fiscal and monetary policy tightening has so far managed to slow demand growth sharply without accidentally overdoing it and sparking a recession, an impressive achievement,” Goldman Sachs economists stated in a recent note to their clients (https://ibn.fm/7HK1I). Specialized financing company REZYFi is pursuing a growth strategy cognizant of the economic pressures, preparing to launch a high-margin cannabis division later this year while managing staffing levels and applying proprietary technologies for efficiency. The cannabis industry has historically struggled with obtaining loans and other bank services because of the U.S. government’s continued regulation of the leafy green plant as a highly controlled substance. State governments have created legalized avenues for the cannabis market in recent years, but the industry continues to hope for better financing conditions, such as those proposed under the Secure and Fair Enforcement (“SAFE”) Banking Act and the Marijuana Opportunity Reinvestment and Expungement (“MORE”) Act that have cleared the House of Representatives and are awaiting a decision from the Senate. The measures would prevent federal regulators from penalizing banks that serve the cannabis industry or decriminalize cannabis outright (https://ibn.fm/C25wP). For REZYFi, all of this has created a significant window of opportunity, of which the company has taken advantage. As a result, the company is now licensed in more than 30 U.S. states, with expectations to expand its loan origination and services to all remaining states. For more information, visit the company’s website at www.REZYFi.com. NOTE TO INVESTORS: The latest news and updates relating to REZYFi are available in the company’s newsroom at https://ibn.fm/REZY

• Climate change and industrialized pollution emissions continue to raise warnings worldwide that the quality of human life is being compromised
• U.S.-based Correlate Infrastructure Partners is working to establish solutions for its clients by assessing utilities inefficiencies, advising on affordable improvements, and then helping to successfully implement changes through access to highly cost-effective financing opportunities
• The federal government’s recent passage of greenhouse gas reduction financing opportunities through the Inflation Reduction Act (“IRA”) has established the government as a ready partner in companies’ ESG policies
• The IRA has become particularly attractive to public, non-profit, and REIT entities because of changes to subsidy availability
• A low increase in global carbon dioxide emissions associated with energy use this year shows that industries are finding increased motivation to improve their greenhouse gas profiles

Progressive tech hub Seattle, where Amazon and Microsoft are headquartered, made headlines last month for an age-old problem — pollution, when Seattle, helped by wildfires, was briefly classified as the worst city worldwide for air quality and pollution, and was kept among the planet’s top polluters for a while even after it fell out of the top spot (https://ibn.fm/rploW). While wildfires and unusually hot, dry climate conditions were blamed for the spike in poor air quality (https://ibn.fm/LIRap), more than a third of the city’s persistent greenhouse pollutants are attributed to climate-unfriendly energy use by residential, commercial and industrial buildings. Efforts to curb the building pollution, not just in Seattle but across the Washington state, has led Washington’s Building Code Council to require heat pump installation in large and commercial buildings by July in a bid to increasingly electrify utilities and move away from carbon-based fuels (https://ibn.fm/9bgta). Clean energy solutions innovator Correlate Infrastructure Partners (OTCQB: CIPI) is committed to facilitating improvements in greenhouse gas reduction through correlated efforts by its subsidiaries to advise the commercial real estate industry (companies that develop and rent out commercial building properties) on opportunities to change their carbon pollutant output and then help them implement those changes with available financing solutions. The Inflation Reduction Act (“IRA”) recently passed by the Biden administration is credited for opening up financing for a large number of pollution-reducing, climate-positive efforts through energy-related tax credits. Subsidies for energy efficiency retrofits and renewable energy installations are expected to be particularly useful for tax-exempt public and non-profit entities as well as real estate investment trusts (“REITs”) because those entities have thus far been unable to find financial incentive to improve their ESG profiles because they don’t have taxable income for decarbonization tax credits to offset. “We can now take 20-30% off the top of capital projects that we would typically need to pass on. Reducing that up front cost opens up a new playbook,” the vice president of REIT Macerich’s Corporate Responsibility and Sustainability division told smart building tech community Nexus Pro last month (https://ibn.fm/QGc8f). Some climate activists have gone so far as to encourage the president to use “the full powers of the federal government” to require huge cuts to building emissions nationwide (https://ibn.fm/eJahH) but Correlate Infrastructure Partners is optimistic that the trend toward increasing ESG investment by the younger generation (https://ibn.fm/YHSVQ) is helping to motivate companies to  clean their own houses. An Oct. 20 report by Scientific American noted that global carbon dioxide emissions associated with energy use are on track to increase 1 percent this year but added that the 1 percent increase is “significantly less than what many observers projected earlier this year” and a landmark step in creating continued climate change solutions (https://ibn.fm/XjgSP). For more information, visit the company’s website at www.CorrelateInfra.com, including the following:

• Breaking Down Barriers To Your ESG Goals While Generating Additional Net Operating Income: www.CorrelateInfra.com/our-process
• Platform Generates New Rent And Operating Income, Allowing You To Meet Your ESG Goals: www.CorrelateInfra.com/program

NOTE TO INVESTORS: The latest news and updates relating to CIPI are available in the company’s newsroom at https://ibn.fm/CIPI

• The CCPA limits data flows to brands and marketers, and CPRA amendments are set to take effect January 1, 2023
• CPRA and CCPA provisions include the right to opt-out of data sharing and sale, as well as the right to data deletion
• Consumer data is critical to branding and advertising strategies
• Reklaim provides an ecosystem that equips marketers with fully compliant, consumer-verified data sets while rewarding consumers for sharing information

With the aim of protecting consumers, the California Consumer Privacy Act (“CCPA”) and amendments provided by the California Privacy Rights Act (“CPRA”) are gradually transforming the advertising landscape by limiting data flows to brands and advertisers. Reklaim (TSX.V: MYID) (OTCQB: MYIDF) is firmly positioned to fill the void with a privacy-compliant desktop and mobile identity ecosystem that provides relevant datasets to marketers while rewarding consumers for sharing their data. Data fuels the company’s need to market activities for brands and advertisers. However, options are gradually decreasing due to privacy laws restricting information flow of information to the market. One such law is the CCPA, which took effect on January 1, 2020, and is set to be amended by the CPRA on January 1, 2023 (https://ibn.fm/UbGB0). The CCPA’s initial provisions give consumers the right to know what data is collected, why it is collected, if it is sold and what party bought the information. They also offered the right to delete this data. The CPRA adds two additional provisions: the right to correct inaccurate personal information and the right to limit the use and disclosure of sensitive personal data. The CCPA and subsequent CPRA amendments impose these obligations on businesses, service providers, contractors and third parties. Consequences for non-compliance include penalties of up to $7,500 per intentional violation, $2,500 per unintentional violation and statutory damages of up to $750 per consumer per incident. California is the world’s sixth-largest economy, ahead of Italy and closely behind France (https://ibn.fm/nzX82), making it a highly lucrative jurisdiction for brands and advertisers. In addition to severely limiting marketing activities in the United States, similar laws enacted in other countries threaten to greatly reduce the impact of advertising campaigns worldwide (https://ibn.fm/QLTnl). Reklaim is strongly positioned to support brands with fully consensual, consumer-verified data through an ecosystem that rewards users for sharing their data while providing verified datasets advertisers can access for a fee. Besides being fully compliant, Reklaim’s platform offers more relevant and higher-quality data, because consumers on the platform actively provide and choose to share their information. According to Fortune Business Insights, the global customer data platform market was valued at $1.42 billion in 2022 and is expected to reach $6.94 billion by 2029, expanding at a CAGR of 25.4% over the forecast period (https://ibn.fm/ZCUUC). As demand for consumer data continues to rise amid legislative restrictions, Reklaim provides valuable, transparent and high-quality solutions that benefit both sides of the consumer data market. For more information, visit the company’s website at www.ReklaimYours.com. NOTE TO INVESTORS: The latest news and updates relating to MYIDF are available in the company’s newsroom at https://ibn.fm/MYIDF

• CNS Pharmaceuticals is focused on advancing its clinical development for the Berubicin drug candidate in order to bring meaningful treatment to GBM patients
• GBM, which has a low survival rate, has limited treatment options when it progresses after first-line therapy
• The company is looking to find a solution with Berubicin and is currently evaluating this drug candidate in a potentially pivotal global study
• CNS’s ongoing R&D efforts are boosted by its strong cash position; in its Q2 2022 report, the company announced it had cash of about $9.0 million and working capital of $10.5 million

CNS Pharmaceuticals (NASDAQ: CNSP), an oncology drug development company specializing in developing anti-cancer drugs for the treatment of primary and metastatic brain and central nervous system (“CNS”) cancer, started 2022 on a high, closing an $11.5 million private placement whose net proceeds the company intended to deploy toward funding its clinical trials and preclinical programs as well as other research and development (“R&D”) activities and general corporate purposes. The additional funding not only boosted the company’s R&D efforts but also enhanced its cash position, as reflected in its subsequent financial reports (https://ibn.fm/GK93f). In its report for the three months ended June 30, 2022 (“Q2 2022”), CNS Pharmaceuticals had cash and cash equivalents of about $9.0 million and working capital of $10.5 million (https://ibn.fm/UiG9a). And although the figure represented a drop from about $12.4 million and $13.7 million, respectively, recorded in the period ended March 31, 2022 (“Q1 2022”) (https://ibn.fm/ycZXd), the company spent 46% more on R&D in Q2 2022 than in Q1 2022. (Its R&D expenditure in Q2 2022 was $2.2 million.) CNS Pharmaceuticals expects its cash on hand and proceeds from the placement to fund its operations into Q1 2023. The first half of fiscal 2022 saw the company make a number of clinical and operational advancements in its pursuit of treatment for Glioblastoma Multiforme (“GBM”), according to CNS Pharmaceuticals CEO John Climaco. The company’s focus and priorities, Climaco emphasized, are firmly anchored in the advancement of its clinical development for its drug candidate Berubicin with the aim of bringing meaningful treatment to GBM patients. And as he separately told attendees at the recently held H.C. Wainwright 24th Annual Global Investment Conference, this focus is driven by a significant unmet clinical need, especially given that recurrent GBM does not have “an approved therapy anywhere in the world” (https://ibn.fm/ciFue). For GBM patients, this unmet need causes anguish that often culminates in death. A 2021 study, for instance, notes, “Once tumors progress after first-line therapy, treatment options are limited, and the management of recurrent GBM remains a challenge” (https://ibn.fm/4ZfEE). Another, a 2015 study, underlines that recurrence is, unfortunately, inevitable, with its management unclear and case-dependent (https://ibn.fm/DRKYF). These characteristics have meant that GBM remains one of the most aggressive primary brain tumors, with a grim prognosis. Data from the American Cancer Organization shows that GBM has the least 5-year relative survival rate of the various common adult brain and spinal cord tumors in the list. For example, among 20- to 44-year-old patients, the survival rate stands at 22%. This figure drops to 9% among adults aged between 45 and 54 and 6% among those between 55 and 64. In comparison, anaplastic astrocytoma, the condition with the second lowest survival rate in the list, has higher survival rates of 58%, 29%, and 15%, respectively, across the three age categories (https://ibn.fm/IR0ko). The condition’s aggressiveness is further concretized by the fact that over 10,000 patients succumb to GBM annually in the United States, where 13,000 people are diagnosed with GBM every year the average length of survival for GBM patients is estimated to be only eight months. (https://ibn.fm/hUVew). With the survival rate and mortality statistics for GBM remaining virtually unchanged for decades, according to the National Brain Tumor Society, CNS Pharmaceuticals is working hard to find a solution. The company is relying on Berubicin, a novel anthracycline whose mechanism of action is inhibiting the topoisomerase II enzyme that causes cell replication and is abundantly found in tumor cells. CNS Pharmaceuticals has observed that the drug, which appears, based on limited clinical data, to cross the blood-brain barrier, is selectively absorbed in cancerous cells and tissue in the brain. The Berubicin drug candidate solves a problem that has long dogged cancer research for years. Although anthracyclines have existed for the past six decades, they could not cross the blood-brain barrier. CNS Pharmaceutical’s drug candidate, therefore, is the first anthracycline to appear to cross this critical barrier. The company is currently undertaking a potentially pivotal global study evaluating the efficacy and safety of Berubicin compared with Lomustine administered after first-line therapy for the treatment of recurrent GBM. For more information, visit the company’s website at www.CNSPharma.com. NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP